Biomarker prediction of immunotherapy response in breast cancer: from single markers to multi-omics integration.

NPJ Breast Cancer · 2025 · PMC12800120 · PMID 41366250

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

KEYNOTE-119, however, used pembrolizumab as monotherapy, and results showed a trend toward OS improvement at CPS ≥ 10 and more robust effects at CPS ≥ 20 13 , 14 .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.